Immuneering Corp — Director's Dealing 2023

Jun 15, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2023-06-14

Reporting Person: Feinberg Peter (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-14	Stock Option	$9.32	A	17500	Acquired	2033-06-14	Class A Common Stock (17500)	Direct

Footnotes

F1: The option vests and becomes exercisable in substantially equal monthly installments over a one-year period with a vesting commencement date of June 14, 2023, and will be fully vested and exercisable on June 14, 2024, or the date of the 2024 annual meeting of stockholders, whichever comes first.